TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00709397

Intervention type: OTHER
Intervention: blood drawing
Description: Subjects will have been prescribed raltegravir (400 mg BID) by their primary physicians. Such subjects will have frequent blood sampling in this study to monitor the virologic response to raltegravir therapy.
Study: NCT04221789

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TB treatment assistant
Description: Cell phone app to support self administered treatment and monitor adherence
Study: NCT04427176

Intervention type: DEVICE
Intervention: ARFC mask
Description: Nurse will wear the ARFC mask during working days. The total duration of the study will be 48 hours for each participant, 2 consecutive working days of 8 or 12 hours.
Study: NCT00682227

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: TTK, LY6K, and IMP-3 peptides
Description: Each of three peptides (1mg) mixed with IFA (1ml) were injected every week at five round.
Study: NCT04042753

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 3 mg/kg every 3 weeks,

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab 1 mg/kg every 3 weeks for 4 cycles

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Following concurrent ipilimumab and nivolumab, patients will receive single agent nivolumab at 480 mg every 4 weeks for 6 cycles (1 cycle=4 weeks) with the option of continuing until disease progression or until the end of the study, whichever occurs first
Study: NCT01459146

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Artemether-lumefantrine combination plus albendazole
Description: AL: 20mg/120mg 12-hourly orally for 3 days ABZ: 400mg oral stat

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Artemether-lumefantrine plus Praziquantel plus Albendazole
Description: Artemether-lumefantrine 20mg/120mg 12 hourly for 3 days, plus praziquantel 40mg/kg stat, plus albendazole 400mg stat oral

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Albendazole plus Praziquantel
Description: Albendazole 400mg stat plus Praziquantel 40mg/kg stat oral
Study: NCT00891046

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Canakinumab
Description: Canakinumab
Study: NCT00573456

Intervention type: RADIATION
Group type: OTHER
Intervention: Far Infrared Radiation
Description: Far Infrared Radiation (5μm to 20μm wavelength) for 30 to 40 minutes per session.
Study: NCT00362375

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Healthy Love Workshop
Description: The Healthy Love Workshop is a single-session intervention lasting 3-4 h that is typically delivered to groups of 4-15 women; however, SisterLove facilitators can accommodate larger groups if needed. The intervention is designed to increase consistent use of condoms and other latex barriers, reduce unprotected sex with male partners, and reduce the number of sex partners. HLW also promotes sexual abstinence, HIV testing, and receipt of test results.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: HIV/AIDS 101 Workshop
Description: The comparison workshop (named HIV101) was also delivered as a single session lasting 2-3 h, to groups of women about the same size and in settings similar to those used for the HLW. The HIV101 workshop consists of an opening, one module containing the same three HIV/STD-related components as the HLW (HIV/AIDS facts, STI facts, and the Look of HIV) and a closing. However, the presentation of this information used a didactic, lecture-style format, as opposed to the interactive approach used to deliver the HLW.
Study: NCT05869695

Intervention type: OTHER
Intervention: OSPRO-ROS Questionnaire
Description: Completion of questionnaires

Intervention type: OTHER
Intervention: OSPRO-YF Questionnaire
Description: Completion of questionnaires
Study: NCT03215953

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: cast shoe
Description: ankle-high, custom-made, well-moulded cast shoe

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: removable walker
Description: Prefabricated especially designed for relieving load on the foot
Study: NCT00522743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: growth hormone and gonadotropin-releasing hormone agonist
Description: GH \& GNRHa treatment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: growth hormone
Description: GH treatment
Study: NCT01710059

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Asthma Supervision
Description: Each participant will be provided with a spacer and a peak flow meter, and instructions on proper technique, by a member of the study team during the baseline period. They will also meet with study staff at study visits during the active treatment phase to review their adherence to daily inhaled corticosteroids and usage patterns of short acting B2-agonist medication.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mobile Phone
Description: Each participant will receive a mobile phone with talking, texting and a data plan. They will get to keep the mobile phone at the end of the study, but the talking, texting and data plan will only be active during their participation in the study.
Study: NCT00642954

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat 300 mg or 400 mg QD via oral capsule on Days 1-7 and Days 15-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat 300 mg or 400 mg QD via oral capsule on Days 1-7 and Days 15-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat 300 mg or 400 mg QD via oral capsule on Days 1-7 and Days 15-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat 300 mg or 400 mg QD via oral capsule on Days 1-7 and Days 15-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Description: Vorinostat 300 mg or 400 mg QD via oral capsule on Days 1-7 and Days 15-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 10 mg, 15 mg, 20 mg or 25 mg QD via oral capsule on Days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 10 mg, 15 mg, 20 mg or 25 mg QD via oral capsule on Days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 10 mg, 15 mg, 20 mg or 25 mg QD via oral capsule on Days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 10 mg, 15 mg, 20 mg or 25 mg QD via oral capsule on Days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Lenalidomide 10 mg, 15 mg, 20 mg or 25 mg QD via oral capsule on Days 1-21 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg QD via oral tablet on Days 1, 8, 15 and 22 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg QD via oral tablet on Days 1, 8, 15 and 22 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg QD via oral tablet on Days 1, 8, 15 and 22 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg QD via oral tablet on Days 1, 8, 15 and 22 of each 28-day cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: Dexamethasone 40 mg QD via oral tablet on Days 1, 8, 15 and 22 of each 28-day cycle.
Study: NCT02641405

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Equistasi
Description: Equistasi is a nanotechnology for proprioceptive focal stimulation. Every patient will receive three patches to be placed at C7 and at the gastrocnemial junction of both legs.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Inactive Equistasi
Description: Inactive Equistasi will be given to every patient in the form of three patches to be placed at C7 and at the gastrocnemial junction of both legs.
Study: NCT01710059

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Inhaled Corticosteroid Mobile Phone Application
Description: The Inhaled Corticosteroid Mobile Phone Application will be used to provide virtual doctor supervision, immediate feedback, and positive reinforcement for taking inhaled corticosteroid medication as indicated.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Beta2-adrenergic agonist Mobile Phone Application
Description: The Beta2-adrenergic agonist Mobile Phone Application will be used to track real time patterns of use of beta2-adrenergic agonist medication.
Study: NCT03922022

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EIM exercise classes and intervention
Description: This is a complex intervention. On recruitment, they will be seen by a nurse and counselled using motivational technique. They will then undergo a 12-week class. The exercise levels will be regularly feedback to the patients by use of mobile devices and trackers. Peer support is formed during the 12-week class. Resources to continue exercise will be provided to patients. Regular monitoring of physical improvement will be feedback to patients to encourage continued exercise.
Study: NCT02022722

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trigger Point Injections Triamcinolone Acetonide, Bupivacaine Hydrochloride
Description: The mixture is injected into the levator muscles, with half the volume on each side of the pelvic musculature.
Study: NCT01390428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Part 1: oral morning dose of 200 mg daily for 10 days Part 2: oral morning dose of 100 mg daily for 10 days Part 3: oral morning dose of 50 mg daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Part 1: oral morning dose of 200 mg daily for 10 days Part 2: oral morning dose of 100 mg daily for 10 days Part 3: oral morning dose of 50 mg daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Part 1: oral morning dose of 200 mg daily for 10 days Part 2: oral morning dose of 100 mg daily for 10 days Part 3: oral morning dose of 50 mg daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Part 1: oral morning dose of 200 mg daily for 10 days Part 2: oral morning dose of 100 mg daily for 10 days Part 3: oral morning dose of 50 mg daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Part 1: oral morning dose of 200 mg daily for 10 days Part 2: oral morning dose of 100 mg daily for 10 days Part 3: oral morning dose of 50 mg daily for 10 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Grazoprevir
Description: Part 1: oral morning dose of 200 mg daily for 10 days Part 2: oral morning dose of 100 mg daily for 10 days Part 3: oral morning dose of 50 mg daily for 10 days
Study: NCT01051440

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lisdexamfetamine
Description: Start at 20 mg daily. Increased to a maximum of 40 mg daily. Can be decreased in 10 mg increments.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subjects will receive placebo matched to lisdexamfetamine.
Study: NCT03264534

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: limbal relaxing incisions
Description: Manually performed surgical procedure

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: astigmatic keratotomy
Description: femtosecond laser guided surgical procedure
Study: NCT04780633

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Precede-Proceed based Training Program on Genital Hygiene Behaviors
Description: A Training Program for Genital Hygiene Behaviors prepared in line with the Precede-Proceed model was presented to the women in the experimental group. The trainings started one week after the pre-test data were collected and were conducted in a total of 5 sessions, each lasting an average of 40 minutes, once a week. At the end of the five-week training, a post-test was applied. In order to determine the behavior changes of the women in the experimental group, a follow-up test was applied 4 weeks after the training ended. At the end of the training, women were given a training booklet prepared by the researcher.
Study: NCT02352376

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional ventilator
Description: A ventilator designed for invasive ventilation was used has mode non-invasive ventilation with leakage compensation (50% of the predetermined tidal volume).

Intervention type: OTHER
Group type: OTHER
Intervention: Conventional ventilator
Description: A ventilator designed for invasive ventilation was used has mode non-invasive ventilation with leakage compensation (50% of the predetermined tidal volume).
Study: NCT02022722

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pelvic Rehabilitation
Description: Pelvic floor massage will be performed on a weekly basis by a licensed physiotherapist specialized in pelvic floor pelvic therapy
Study: NCT02352376

Intervention type: OTHER
Group type: OTHER
Intervention: Specific ventilator
Description: A ventilator was used designed for non-invasive ventilation has an algorithm that calculates the loss of pressure and automatically compensates for leak
Study: NCT03253263

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OHB-607
Description: Participants will receive intravenous infusion of OHB-607 from birth up to PMA 29 weeks + 6 days.
Study: NCT02906020

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venglustat GZ/SAR402671
Description: Pharmaceutical form: capsule Route of administration: oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Pharmaceutical form: capsule Route of administration: oral
Study: NCT02928601

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: After spinal anesthesia, half of the patients will be given intravenous 8 mg ondansetron.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Saline
Description: After spinal anesthesia, half of the patients will be given intravenous 2 mlt saline.
Study: NCT02984644

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dapagliflozin
Description: Three 5-hour measurements (after dapagliflozin 10mg administration) of endogenous glucose production (EGP) will be performed on separate days.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Three 5-hour measurements (after placebo administration) of endogenous glucose production (EGP) will be performed on separate days.
Study: NCT01530711

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Terlipressin and albumin
Description: Terlipressin dose: 2mg/24h, it will be modified depending on: Arterial pressure increase \< 10 mmHg and the creatinine values decrease \<25%, it will be increased every 8 hours until reaching an increase of at least 10mmHg arterial pressure or a creatinine decrease of the 25%.~Albumin: Initial dose (first day) of 1g/Kg (up to a maximum of 100g) and the following days from 20 to 40 g/day.
Study: NCT00182533

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: 25 - 200 mg/day x 16 weeks

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 25 - 200 mg/day x 16 weeks
Study: NCT02986347

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous regional anesthesia (Bier)
Description: Intravenous regional anesthesia (Bier Technique)

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Local anesthesia with adrenaline
Description: local anesthesia with adrenaline without limber garroting (Lalonde Technique)
Study: NCT03054285

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Participants assigned to the experimental arm will receive a seven day course of levetiracetam for post-traumatic brain injury
Study: NCT01738256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellbeing intervention (ACT)
Description: The intervention is based on principles of acceptance-commitment therapy (ACT). It aims to increase psychological flexibility through different exercises that are developed for improving skills of being present, dealing with thoughts and feelings, as well as support clarifying individual values and value-based actions. In addition exercises for relaxation, physical activity, and mindful eating are provided. The content of intervention for face-to-face and mobile groups is similar but delivery method is different.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellbeing intervention (ACT)
Description: The intervention is based on principles of acceptance-commitment therapy (ACT). It aims to increase psychological flexibility through different exercises that are developed for improving skills of being present, dealing with thoughts and feelings, as well as support clarifying individual values and value-based actions. In addition exercises for relaxation, physical activity, and mindful eating are provided. The content of intervention for face-to-face and mobile groups is similar but delivery method is different.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Wellbeing intervention (Internet)
Description: The intervention is Duodecim Virtual Health Check and Coaching where the subject gets feedback based on his/her health information and is provided with different weekly tasks regarding lifestyle changes. The tasks are developed based on principles of cognitive behaviour therapy (CBT).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No intervention
Description: No intervention
Study: NCT00781924

Intervention type: PROCEDURE
Intervention: biopsy
Description: ultrasound guided biopsy of tumors.
Study: NCT02701062

Intervention type: DEVICE
Group type: OTHER
Intervention: AtriClip® Gillinov-Cosgrove™ LAA Exclusion Systems

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Anticoagulation Therapy
Description: Anticoagulation Therapy- Standard of Care at the discretion of the Investigator.
Study: NCT02641587

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: CHTP 1.2
Description: Ad libitum use of the CHTP 1.2 for 5 days in confinement followed by 85 days in an ambulatory setting.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: CC
Description: Ad libitum use of subject's own preferred non-menthol brand of CC for 5 days in confinement followed by 85 days in an ambulatory setting.
Study: NCT03207308

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Description: 200,000 IU of preformed vitamin A
Study: NCT04692272

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise in the XBOX kinect
Description: The XBOX group performed exercise for 60 min, three times/week, for 6 weeks, using the Xbox Kinect game Your Shape Fitness evolved. This game was chosen because it simulates an environment with a variety of physical activities, in which the majority can be practiced by older adults. The activities were carried out individually. The game activities selected for the physical activity sessions were: 1) Zen-Develop it (stretching, balance and flexibility activities, similar to Yoga); 2) Pump it (to fill balls until they burst); 3) Wall Breaker (to break blocks, similar to boxing); 4) Kick it (soccer activity); 5) Hurricane (to lift the balls off the floor and not let them fall); 6) Stack in Up (balance activity).
Study: NCT00729300

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: 0mg daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: disulfiram
Description: 250mg daily
Study: NCT00698282

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: Oral tablet, 250 mg single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD1981
Description: Suspension, 15, 75, 1000 and 2000 mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT04200222

Intervention type: DIAGNOSTIC_TEST
Intervention: cadmium, lead and vanadium measurements and compare
Description: The method developed by Aliyev et al. was used for preparing the samples for analysis (1).~The three metals (cadmium, lead and vanadium) were measured using inductively coupled plasma-mass spectrometry (Thermo Scientific ICAPQc, USA).~1. Ovayolu A, Ovayolu G, Karaman E, Yuce T, Ozek MA, Turksoy VA. Amniotic fluid levels of selected trace elements and heavy metals in pregnancies complicated with neural tube defects. Congenit Anom (Kyoto). 2019:10.1111/cga.12363.

Intervention type: DIAGNOSTIC_TEST
Intervention: cadmium, lead and vanadium measurements and compare
Description: The method developed by Aliyev et al. was used for preparing the samples for analysis (1).~The three metals (cadmium, lead and vanadium) were measured using inductively coupled plasma-mass spectrometry (Thermo Scientific ICAPQc, USA).~1. Ovayolu A, Ovayolu G, Karaman E, Yuce T, Ozek MA, Turksoy VA. Amniotic fluid levels of selected trace elements and heavy metals in pregnancies complicated with neural tube defects. Congenit Anom (Kyoto). 2019:10.1111/cga.12363.
Study: NCT05227781

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: L-Citrulline
Description: 8 weeks of L-Citrulline supplementation (10 grams/day)

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 8 weeks of Placebo (maltodextrin; 10 grams/day)
Study: NCT03167853

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: humanized anti-PD-1 monoclonal antibody
Description: humanized anti-PD-1 monoclonal antibody(JS001) is a programmed death-1 (PD-1) immune checkpoint inhibitor antibody, which selectively interferes with th combination of PD-1 with its ligands, PD-L1 and PD-L2, resulting in the activitation of lymphocytes and elimination of malignancy theoretically.
Study: NCT01828086

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CJM112
Description: Monoclonal antibody

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Secukinumab
Description: Monoclonal antibody

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Liquid for subcutaneous injection without active drug.
Study: NCT03965676

Intervention type: OTHER
Group type: OTHER
Intervention: Dual-Energy Computed Tomography examination
Description: Dual-Energy Computed Tomography examination at 6 and 12 months +/- 1 month of medical treatment with uricemia \< 360μmol/L (baseline DECT is in the domain of usual care).
Study: NCT03234946

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: CAIPaDi
Description: Patients are attended in 1 day by 9 specialists (endocrinologist, diabetes educators, nutritionist, psychologist, physical activity specialist, foot care and ophthalmologist). They are attended in 4 monthly visits. After the initial phase, patients come back to the Center at 1 and 2 years for evaluation and reinforcement